Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of D609 in preparation of medicine for preventing and treating retinal injury diseases

A technology for retinal damage and retinal pigment, which is applied in the field of biomedicine to achieve strong protective effects, reduce damage, and high efficacy

Active Publication Date: 2020-02-14
广州因明生物医药科技股份有限公司
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are no relevant reports at home and abroad on the effect of D609 on RPE cells under oxidative stress. Whether D609 may delay the occurrence and development of AMD by reducing the oxidative stress damage of RPE cells remains to be studied.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of D609 in preparation of medicine for preventing and treating retinal injury diseases
  • Application of D609 in preparation of medicine for preventing and treating retinal injury diseases
  • Application of D609 in preparation of medicine for preventing and treating retinal injury diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] (1) method

[0066] 1. Experimental materials and procedures

[0067] 1.1 Cell culture medium preparation: DMEM / F12+10% fetal bovine serum+1% P / S double antibody.

[0068] 1.2 Preparation of various antioxidants: Dilute different antioxidants separately, and use a concentration of 10 μg / mL.

[0069] 1.3 Preparation of sodium iodate: Sodium iodate (SI) was directly diluted with culture medium, and the final concentration was 10 mM.

[0070] 1.4 Treatment of cells:

[0071] The retinal pigment epithelial cell line ARPE-19 cells purchased from ATCC will be cultured in the medium of DMEM / F12+10% fetal bovine serum+1% double antibody, and divided into negative control group and model control group (sodium iodate) 1. Experimental group: Sodium iodate + various antioxidants were co-treated separately. Place at 37°C, 5% CO 2 Cultivated in an incubator. Observe cell changes and perform corresponding molecular biology tests.

[0072] (2) Results

[0073] The results are s...

Embodiment 2

[0081] (1) method

[0082] 1. Experimental materials and procedures

[0083] 1.1 Cell culture medium preparation: DMEM / F12+10% fetal bovine serum+1% P / S double antibody

[0084] 1.2 D609 preparation: Dilute D609 powder with ultrapure water, the final concentration is 5mg / mL, and the final use concentration is 10μg / mL.

[0085] 1.3 Preparation of sodium iodate: Sodium iodate (SI) was directly diluted with culture medium, and the final concentration was 10 mM.

[0086] 1.4 Treatment of cells:

[0087] The retinal pigment epithelial cell line ARPE-19 cells purchased from ATCC will be cultured in the medium of DMEM / F12+10% fetal bovine serum+1% double antibody, and divided into negative control group and model control group (sodium iodate) , Experimental group 1: sodium iodate + D609, experimental group 2: D609. Place at 37°C, 5% CO 2 Cultivated in an incubator. In the experimental group 1, D609 was added to the medium containing 10 mM sodium iodate and diluted to 10 μg / mL, ...

Embodiment 3

[0094] Example 3 Cell Viability Experiment (CCK8 Staining)

[0095] (1) Method

[0096] 1. Experimental materials and procedures

[0097] 1.1 Cell culture medium preparation: DMEM / F12+10% fetal bovine serum+1% P / S double antibody

[0098] 1.2 D609 preparation: Dilute D609 powder with ultrapure water, the final concentration is 5 mg / mL, and the final use concentration is 10 μg / mL.

[0099] 1.3 Sodium iodate preparation: The sodium iodate powder was directly diluted with culture medium, and the final concentration was 10mM.

[0100] 1.4 Cell preparation: ARPE-19 cells, a retinal pigment epithelial cell line purchased from ATCC, were seeded into 96-well plates, with 10,000 cells per well, and cultured for 48 hours. Divided into negative control group, model control group (sodium iodate), experimental group 1: sodium iodate + D609, experimental group 2: D609. In the experimental group 1, D609 was added to the medium containing 10 mM sodium iodate and diluted to 10 μg / mL, and t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of D609 in preparation of a medicine for preventing and treating retinal injury diseases. The Chinese name of D609 is tricyclic decane-9-yl-dithiocarbonate potassium salt, and the D609 is an antiviral and antitumor small molecular compound, which belongs to a selective inhibitor of phosphatidylcholine specific phospholipase (PC-PLC). According to the invention, the wide and deep research is carried out, the unexpected discovery is realized for the first time, the expression of metallothionein is up-regulated by the D609; the oxidative damage of RPE cellscan be effectively inhibited; therefore, the compound can be used for preventing or treating retinal injury diseases caused by oxidative stress injury of retinal pigment epithelial cells, especially,the compound can be extremely effectively used for preventing or treating macular degeneration diseases of retina, has no obvious drug toxicity, can effectively control the occurrence and developmentof injury diseases of retina, and provides a new theoretical support for developing unknown biological activity of D609 and future clinical treatment effects.

Description

technical field [0001] The invention belongs to the technical field of biomedicine. More specifically, it relates to the application of tricyclic decanan-9-yl-dithiocarbonate potassium salt (D609) in the preparation of drugs for the prevention and treatment of retinal damage diseases, and opens up new possibilities for the prevention and clinical treatment of ophthalmology-related diseases. methods and ideas. Background technique [0002] The retinal pigment epithelium (RPE) is a layer of pigmented cells that adheres closely to the subretina. It is a neatly arranged single layer of hexagonal cells located between the optic nerve retina and Brunch's membrane. Maintaining the normal physiological function of RPE plays an important role in the normal reception and transmission of photoreceptor signals, mainly in: 1) regulating the transport of nutrients from choroidal capillaries to photoreceptor cells; 2) absorbing light, improving the quality of the visual system and reducin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/265A61K45/06A61P9/10A61P27/02
CPCA61K31/265A61K45/06A61P9/10A61P27/02A61K2300/00
Inventor 欧阳宏王力
Owner 广州因明生物医药科技股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com